NCT03808480 2022-04-06Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%National Cancer Center, KoreaPhase 2 Unknown22 enrolled
NCT04142931 2021-03-24Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid TumorsSheba Medical CenterPhase 1 Unknown30 enrolled
NCT04331626 2020-04-02Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLCHenan Cancer HospitalPhase 4 Unknown50 enrolled